Agios Pharmaceuticals, Inc. (AGIO) – What Are Analysts Thinking About This Stock?

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $42.12.

A number of brokerages recently weighed in on AGIO. HC Wainwright upped their target price on shares of Agios Pharmaceuticals from $55.00 to $62.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. TD Cowen raised shares of Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings lowered Agios Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday. JPMorgan Chase & Co. lifted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. Finally, Bank of America lifted their target price on Agios Pharmaceuticals from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, September 21st.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the transaction, the insider owned 54,645 shares in the company, valued at $2,059,570.05. This trade represents a 12.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 9,855 shares of company stock worth $371,112. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. Nykredit A S bought a new stake in Agios Pharmaceuticals in the second quarter worth $26,000. Three Bridge Wealth Advisors LLC bought a new position in Agios Pharmaceuticals during the third quarter valued at $27,000. Quantbot Technologies LP bought a new position in Agios Pharmaceuticals during the second quarter valued at $43,000. Integrated Wealth Concepts LLC purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $47,000. Finally, Allworth Financial LP purchased a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $73,000.

Agios Pharmaceuticals News Roundup

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Agios across 2026–2030, including a move to projected profitability in 2030 of $2.01 per share from $0.72. The firm reiterated its Buy rating and $62 price target. Agios Pharmaceuticals analyst estimates
• Positive Sentiment: Bank of America Securities maintained its Buy rating, while another report said Agios’ price target was raised to $62. These endorsements add to the favorable analyst tone. Bank of America Securities maintains Buy rating Agios price target raised to $62
• Neutral Sentiment: A short-interest report says the figure was 0 shares, despite describing a “significant increase,” and gives a zero-day short-interest ratio. The conflicting wording makes this difficult to interpret as a reliable trading signal.
• Negative Sentiment: Truist Financial reportedly trimmed its price target for AGIO, a counterpoint to the more bullish analyst updates; the supplied headline does not state the revised target. Truist Financial trims Agios price target

Agios Pharmaceuticals Stock Up 1.2%

Shares of Agios Pharmaceuticals stock opened at $31.76 on Wednesday. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of -5.03 and a beta of 0.66. The stock’s 50-day simple moving average is $33.19 and its 200-day simple moving average is $31.80. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.15. Agios Pharmaceuticals had a negative return on equity of 34.63% and a negative net margin of 264.76%. The company had revenue of $55.39 million for the quarter, compared to the consensus estimate of $51.65 million. On average, equities analysts expect that Agios Pharmaceuticals will post -5.75 earnings per share for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.